RxDoctor Payments Data

Yongkuma Yongkuma, MD

Internal Medicine · Andalusia, ALNPI 1417148081

Payments from drug & device makers

$334in general payments, 2019–2025

Across 20 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$92
  • GSK$42
  • Otsuka America Pharmaceutical, Inc.$41
  • Nevro Corp.$28
  • Xeris Pharmaceuticals, Inc.$24
  • Merck$24
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$334 in reported general payments places this provider in the 45th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$203,260
Medicare patients
319
Services billed
2,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide146$182,240
OzempicSemaglutide94$103,530
EliquisApixaban134$103,514
GenvoyaElviteg/Cob/Emtri/Tenof Alafen19$87,810
JanuviaSitagliptin Phosphate50$67,526
TrulicityDulaglutide43$50,568
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,369
JardianceEmpagliflozin53$46,204
LinzessLinaclotide37$34,034
XareltoRivaroxaban31$31,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,348
Darunavir23$21,287
EntrestoSacubitril/Valsartan27$20,371
Breo ElliptaFluticasone/Vilanterol22$15,588
BrilintaTicagrelor11$13,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$18$109,030115 claims
MerckJanuvia$24$67,52650 claims
GSKTrelegy Ellipta, Breo Ellipta$42$38,93654 claims
AstraZenecaBrilinta, Breztri Aerosphere, Symbicort$92$37,81572 claims
AbbVieLinzess$14$34,03437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Andalusia

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →